|
Screening model of angiogenesis promoters
|
血管再生促進(jìn)劑篩選模型
|
|
|
Protective model of vascular endothelial injury
|
血管內(nèi)皮損傷保護(hù)模型
|
|
|
PM2. 5. Screening model of drainage promoters
|
PM2.5促排劑篩選模型
|
|
|
Erythrocyte thrombosis model
|
紅細(xì)胞性血栓模型
|
|
|
Mouse bradycardia model
|
小鼠心動(dòng)過緩模型
|
|
|
Embryotoxicity (OECD standard)
|
胚胎毒性（OECD標(biāo)準(zhǔn)）
|
|
|
Cartilage injury model
|
軟骨損傷模型
|
|
|
Screening model of bone development promoters
|
骨骼發(fā)育促進(jìn)劑篩選模型
|
|
|
The incidence of egg coagulation; No heart rate; Hatching rate; The incidence of no somite formation; Incidence of tail non separation;
|
卵凝結(jié)發(fā)生率;無心跳發(fā)生率;孵化率;體節(jié)未形成發(fā)生率;尾部未分離發(fā)生率;
|
|
|
Incidence of developmental toxicity and teratogenicity (brain, jaw, eye, kidney, intestine, trunk / tail / spinal cord / somite, body coloring, circulatory system, body edema, bleeding)
|
發(fā)育毒性與致畸性（腦、下顎、眼、腎臟、腸道、軀干/尾/脊髓/體節(jié)、身體著色、循環(huán)系統(tǒng)、身體水腫、出血）毒性發(fā)生率
|
|
|
Reproductive toxicity and reproductive ability evaluation; Gonadal growth evaluation; Histological sections of gonads;
|
生殖毒性生殖能力評(píng)價(jià);性腺生長(zhǎng)評(píng)價(jià);性腺病理組織切片;
|
|
|
Behavior (touch response, movement influence, light and dark influence);
|
行為學(xué)（觸碰反應(yīng)、運(yùn)動(dòng)影響、光暗影響）;
|
|
|
apoptotic cell
|
凋亡細(xì)胞
|
|
|
Gastrointestinal peristalsis function (autonomic nerve).
|
胃腸蠕動(dòng)功能（植物神經(jīng)）。
|
|
|
Cytochrome P450 analysis
|
細(xì)胞色素P450分析
|
|
|
Promoting tissue regeneration / wound healing
|
促組織再生作用/傷口愈合
|
|
|
Osteotoxicity
|
骨毒性
|
|
|
Bone mineral density (fluorescence signal intensity); Number of vertebrae.
|
骨密度（熒光信號(hào)強(qiáng)度）;脊椎骨數(shù)量。
|
|
|
Behavior
|
行為學(xué)
|
|
|
The incidence of renal capsule edema;.
|
腎包膜水腫發(fā)生率;。
|
|
|
Nephrotoxicity
|
腎毒性
|
|
|
Degree of liver degeneration; Yolk sac size.
|
肝變性程度;卵黃囊大小。
|
|
|
Animal long-term toxicity test
|
動(dòng)物長(zhǎng)期毒性試驗(yàn)
|
|
|
Phenotypic observation
|
表型觀察
|
|
|
Median lethal concentration
|
半數(shù)致死濃度
|
|
|
Mortality; Evaluation of median lethal concentration (LC50).
|
死亡率;半數(shù)致死濃度（LC50）評(píng)價(jià)。
|
|
|
Screening model of antialcoholic agents
|
解酒劑篩選模型
|
|
|
Mitochondrial function
|
線粒體功能
|
|
|
Cardio cerebrovascular
|
心腦血管
|
|
|
Uric acid model
|
尿酸模型
|
|
|
Ocular toxicity
|
眼毒性
|
|
|
inflammatory reaction
|
炎癥反應(yīng)
|
|
|
Number of neutrophils; Expression level of inflammatory factors.
|
中性粒細(xì)胞數(shù)量;炎癥因子表達(dá)水平。
|
|
|
Anaphylactic reaction
|
類過敏反應(yīng)
|
|
|
Intestinal morphology; Intestinal peristalsis requires motor function.
|
腸道形態(tài)學(xué);腸蠕需動(dòng)功能。
|
|
|
Preclinical evaluation of antiviral research and development
|
抗病毒研發(fā)臨床前評(píng)價(jià)
|
|
|
Metabolic system
|
代謝系統(tǒng)
|
|
|
Screening model of gastrointestinal motility inhibitors
|
胃腸動(dòng)力抑制劑篩選模型
|
|
|
Myocardial injury protective agent screening model
|
心肌損傷保護(hù)劑篩選模型
|
|
|
Screening model of renal protective agents
|
腎功能保護(hù)劑篩選模型
|
|
|
Drug stability test
|
藥物的穩(wěn)定性試驗(yàn)
|
|
|
Apoptosis inhibitor screening model
|
凋亡抑制劑篩選模型
|
|
|
Fat metabolism model
|
脂肪代謝模型
|
|
|
Preclinical drug experiment preclinical research (outsourcing entrusted experiment)
|
藥物臨床前實(shí)驗(yàn) 臨床前研究（外包委托實(shí)驗(yàn)）
|
|
|
Efficacy evaluation model of drug efficacy evaluation system
|
藥物功效評(píng)價(jià) 系統(tǒng) 功效評(píng)價(jià)模型
|
|
|
Induction model of high sugar and high fat diet
|
高糖高脂飲食誘導(dǎo)模型
|
|
|
Animal analgesic model
|
動(dòng)物鎮(zhèn)痛模型
|
|
|
Animal modeling technology service
|
動(dòng)物造模技術(shù)服務(wù)
|
|
|
Screening model of P-glycoprotein inhibitors
|
P-糖蛋白抑制劑篩選模型
|
|
|
Preclinical evaluation of cardiac drugs
|
心臟藥物臨床前評(píng)價(jià)
|
|
|
Anti angiogenesis model
|
抗血管形成模型
|
|
|
Safety evaluation
|
安全性評(píng)價(jià)
|
|
|
Modeling animal
|
動(dòng)物造模
|
|
|
Animal hemostatic model
|
動(dòng)物止血模型
|
|
|
Preclinical spinal cord injury experiment
|
臨床前脊髓損傷實(shí)驗(yàn)
|
|
|
Angiogenesis inhibitor screening
|
血管形成抑制劑篩選
|
|
|
Hypolipidemic model
|
降血脂模型
|
|
|
Preclinical evaluation of reproductive toxicity
|
生殖毒臨床前評(píng)價(jià)
|
|
|
Animal movement system model
|
動(dòng)物運(yùn)動(dòng)系統(tǒng)模型
|
|
|
Drug evaluation and testing items (outsourcing entrusted experiment)
|
藥物評(píng)價(jià)檢測(cè)項(xiàng)目（外包委托實(shí)驗(yàn)）
|
|
|
Skin toxicity
|
皮膚毒性
|
|
|
Immunotoxicity
|
免疫毒性
|
|
|
Spleen yang deficiency model
|
脾陽虛模型
|
|
|
Comet experiment; Genotoxicity evaluation.
|
慧星實(shí)驗(yàn);基因毒性評(píng)價(jià)。
|
|
|
Behavioral toxicity
|
行為毒性
|
|
|
Fluorescence signal intensity of hair cells
|
毛細(xì)胞熒光信號(hào)強(qiáng)度
|
|
|
Analgesic drug screening
|
鎮(zhèn)痛藥物篩選
|
|
|
Skeletal muscle
|
骨骼肌肉
|
|
|
Hepatotoxicity (juvenile fish)
|
肝毒性（幼魚）
|
|
|
neurotoxicity
|
神經(jīng)毒性
|
|
|
Vitellogenin (VTG) content detection; The expression of genes related to hypothalamic pituitary gonadal axis was detected.
|
卵黃蛋白原（VTG）含量檢測(cè);下丘腦-垂體-性腺 軸線相關(guān)基因表達(dá)量檢測(cè)。
|
|
|
Incidence of acute toxicity (brain, jaw, eye, kidney, intestine, trunk / tail / spinal cord / somite, body coloring, circulatory system, body edema, bleeding)
|
急性毒性（腦、下顎、眼、腎臟、腸道、軀干/尾/脊髓/體節(jié)、身體著色、循環(huán)系統(tǒng)、身體水腫、出血）毒性發(fā)生率
|
|
|
Drug safety evaluation model index
|
藥物安全性評(píng)價(jià) 評(píng)價(jià)模型 指標(biāo)
|
|
|
Screening model of therapeutic agents for osteoporosis
|
骨質(zhì)疏松癥治療劑篩選模型
|
|
|
Oxygen free radical (ROS) scavenger screening model
|
氧自由基（ROs）清除劑篩選模型
|
|
|
Platelet aggregation thrombosis model
|
血小板聚集性血栓模型
|
|
|
Intestinal mucus secretion function
|
腸道粘液分泌功能
|
|
|
Intestinal digestive function
|
腸道消化功能
|
|
|
Animal movement model
|
動(dòng)物運(yùn)動(dòng)模型
|
|
|
Screening model of energy metabolism regulator
|
能量代謝調(diào)節(jié)劑篩選模型
|
|
|
Animal hybridization experiment
|
動(dòng)物雜交實(shí)驗(yàn)
|
|
|
Tryptase expression level (OD value); Anaphylactic reaction test.
|
Tryptase表達(dá)水平（OD值）;類過敏反應(yīng)檢測(cè)。
|
|
|
Skin irritation; Muscle texture; Quantification of skin apoptotic cells; Skin pigment changes.
|
皮膚刺激;肌肉紋理;皮膚凋亡細(xì)胞定量;皮膚色素變化。
|
|
|
Carcinogenicity (mice)
|
致癌性（小鼠）
|
|
|
Fluorescence signal intensity of apoptotic cells in central nervous system;
|
中樞神經(jīng)凋亡細(xì)胞熒光信號(hào)強(qiáng)度;
|
|
|
Cardiovascular toxicity heart rate; Heart rhythm; The incidence of pericardial edema; Incidence of bleeding; Incidence of changes in blood flow velocity; Incidence of thrombosis
|
心血管毒性心率;心律;心包水腫發(fā)生率;出血發(fā)生率;血流速度變化的發(fā)生率;血栓發(fā)生率
|
|
|
Liver kidney model
|
肝腎模型
|
|
|
Induced qi stagnation and blood stasis thrombosis model
|
誘導(dǎo)氣滯血瘀型血栓模型
|
|
|
Induction model of caspase activity
|
對(duì)Caspase活性的誘導(dǎo)作用模型
|
|
|
Eye size; Ocular apoptotic cells; Ocular vascular area; Ocular histopathology.
|
眼睛大小;眼部凋亡細(xì)胞;眼部血管面積;眼組織病理學(xué)。
|
|
|
Gastrointestinal toxicity
|
胃腸道毒性
|
|
|
Macrophage function
|
巨噬細(xì)胞功能
|
|
|
Pharmacodynamic evaluation model of slimming drugs
|
減肥藥藥效評(píng)價(jià)模型
|
|
|
Genotoxicity
|
基因毒性
|
|
|
Audiotoxicity
|
聽毒性
|
|
|
Fluorescence signal intensity of apoptotic cells (AO staining, TUNEL staining)
|
凋亡細(xì)胞熒光信號(hào)強(qiáng)度（AO染色、TUNEL染色）
|
|
|
Peripheral motor nerve length; Incidence of brain degeneration;
|
周圍運(yùn)動(dòng)神經(jīng)長(zhǎng)度;腦變性發(fā)生率;
|
|
|
Number of hematotoxic neutrophils; Number of macrophages; Number of red blood cells (signal intensity); Blood flow.
|
血液毒性中性粒細(xì)胞數(shù)量;巨噬細(xì)胞數(shù)量;紅細(xì)胞數(shù)量（信號(hào)強(qiáng)度）;血流量。
|
|
|
Screening model of hepatoprotective drugs
|
保肝藥篩選模型
|
|
|
Drug screening model for the treatment of heart failure
|
心衰治療藥物篩選模型
|
|